drugset / Trial / NCT02151526

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

NCT02151526 ↗

Phase 1/2 Completed 7 enrolled Genetix Biotherapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to participants with either transfusion dependent beta-thalassemia (TDT) or sickle cell disease (SCD).

Timeline

Start
2013-06-07
Primary completion
2019-02-26
Completion
2019-02-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject betibeglogene autotemcel Unknown — Intravenous